SCHEMBL20183853

SCHEMBL20183853

CCn1c(=O)cc(C2CCN(CCO)CC2)c2cc(N(C)C(=O)c3ccccc3)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
SLC18A3 Q16572 1/20 0.38
OPRD1 P41143 2/20 0.38
MCHR1 Q99705 1/20 0.37
INSR P06213 1/20 0.37
ITK Q08881 1/20 0.37
ALDH1A1 P00352 3/20 0.36
POLB P06746 1/20 0.36
PTGIR P43119 2/20 0.36
TACR2 P21452 2/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRK1 P41145 1/20 0.36
NPY5R Q15761 1/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20183785 0.91 KDM4E (0.43) LMNASMN1; SMN2SLC18A3OPRD1ITK
SCHEMBL20183842 0.91 KDM4E (0.41) SMN1; SMN2INSRITKALDH1A1NPY5R
SCHEMBL20183851 0.91 ALDH1A1 (0.41) SMN1; SMN2INSRITKALDH1A1NPY5R
SCHEMBL20183888 0.91 MCHR1 (0.43) LMNASMN1; SMN2MCHR1INSRITK
SCHEMBL23256500 0.88 KDM4E (0.42) LMNASMN1; SMN2OPRD1ITKALDH1A1
SCHEMBL20183603 0.88 RORC (0.39) LMNASMN1; SMN2OPRD1INSRITK
SCHEMBL20183870 0.87 ALDH1A1 (0.38) SMN1; SMN2INSRITKALDH1A1NPY5R
SCHEMBL20183634 0.85 MCHR1 (0.36) LMNASMN1; SMN2MCHR1ALDH1A1KDM4E
SCHEMBL20183647 0.84 MCHR1 (0.37) LMNASMN1; SMN2MCHR1ITKALDH1A1
SCHEMBL20183795 0.84 KDM4E (0.38) LMNAINSRITKALDH1A1NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
EP-3563851-B1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORP (JP) 2021-04-21 EP disclosed
EP-3327004-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2020-11-04 EP disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10633343-B2 2020-04-28 US disclosed
US-10633343-B2 2020-04-28 US disclosed
EP-3563851-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM Corporation (JP) 2019-11-06 EP disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
WO-2018124180-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR 富士フイルム株式会社 2018-07-05 WO disclosed
EP-3327004-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Fujifilm Corporation (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987349-B2 Antitumor agent and bromodomain inhibitor BRD4, BRD1, BRD3 LMNA 1830/4885SMN1; SMN2 4557/4885SLC18A3 4864/4885
US-10696637-B2 Nitrogen-containing heterocyclic compound CXCL10, CCL5, CXCR3 LMNA 2949/4885SMN1; SMN2 3085/4885SLC18A3 1401/4885
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR BRD4, BRD1, BRD3 LMNA 1830/4885SMN1; SMN2 4557/4885SLC18A3 4864/4885
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CXCL10, CCL5, CXCR3 LMNA 2949/4885SMN1; SMN2 3085/4885SLC18A3 1401/4885
US-10633343-B2 CXCL10, CCL5, CXCR3 LMNA 3356/4885SMN1; SMN2 3653/4885SLC18A3 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.